prescription extended to any doctor, including in initiation of treatment

To be prescribed in addition to a diet and physical activity.peakSTOCK / iStock / Getty Images Plus / via Getty Images

Lhe prescription and delivery conditions of specialties Wegovy Flextouch (Sémaglutide), Saxenda (Liraglutide) and Mounjaro Kwikpen (shooting) indicated in the treatment of obesity has been modified since June 23, 2025 [1] :

• Before June 23 : initial prescription limited to doctors specializing in endocrinology-diabetology-nutrition or competent in nutrition;
• Since June 23 : possible prescription by any doctor, in initiation and renewal.

These specialties must be prescribed according to the terms provided for by the marketing authorization* (AMM – cf. However, Framed). Similarly, in accordance with the care pathway drawn up by the High Authority for Health (HAS) [2] prescription extended any doctor, including that is to say in second intentionin the event of failure of nutritional management, and in combination with a hypocaloric diet and physical activity.

The National Agency for the Safety of Medicines. In addition, Health Products (ANSM) warns against inappropriate use for weight loss for aesthetic purposes, that is to say in people without overweight, or obesity and who have no health problems related to overweight. Nevertheless, This misuse can expose to serious side effects.

* It is therefore no longer requested to limit the prescription to patients with an initial body mass index (BMI) greater than. equal to 35 kg/m²aged under 65 years of age.

The stake of the equitable access

Prescription extended any doctor, including

The decision to restrict the prescribers for the initiation of a treatment by Wegovy Flextouch, Saxenda and prescription extended any doctor, including Mounjaro Kwikpen was decided by the ANSM in October 2024 to limit the risk of misuse (cf. Our article of October 10, 2024), in accordance with the recommendations of the temporary scientific committee (CST) dedicated to AGLP-1.

After several months of marketing. the ANSM noted that this restriction can limit access to these treatments: « The limitation of the initial prescription to doctors specializing in endocrinology-diabetology-nutrition or competent in nutrition was able to constitute a brake on access for certain patients, due to sometimes important deadlines to consult a specialist. This can also be associated with uneven accessibility to these health professionals according to the territories ».

In addition to this argument. the ANSM notes that there is no new security signal: « The favorable benefit/risk ratio of these drugs is not called into question in the indications for marketing authorization ».

Under surveillance drugs

Whether prescription extended any doctor, including they are used in diabetes or obesity treatment, AGLP1 is double surveillance:

• when using : the CST continues to collect information relating to the use of AGLP-1 in order to adapt, if necessary, the recommendations according to the available data and the observations resulting from the monitoring of these drugs;
• Regarding the security profile:

  • A national pharmacovigilance survey is carried out by the regional pharmacovigilance centers (CRPV) in Montpellier and Limoges, relating to the entire AGLP-1 class since 2019: potential signals have been assessed at European level. If a potential signal was confirmed. appropriate risk reduction measures could be taken;
  • Pharmaco-epidemiology studies by the Scientific Interest Group (GIS) Epi-Phare are continued, in collaboration with the Bordeaux Drugs-Safer Center: the objective is to identify a surrisque and/or better characterize the undesirable effects (in particular gastrointestinal events) of AGLP-1 currently reimbursed.

  &#13.